Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects greater than or equal to 18 years,~* Subjects currently on oral vitamin K antagonist (VKA) therapy,~* An urgent surgical procedure is required within 24 hours of the start of investigational medicinal product (IMP),~* Due to the nature of the procedure, withdrawal of oral VKA therapy and infusion of plasma are also indicated to reverse the VKA effect,~* INR greater than or equal to 2 within 3 hours before start of IMP,~* Informed consent has been obtained.~Exclusion Criteria:~* Subjects requiring urgent surgical procedures where according to the surgeon's clinical judgment, an accurate estimate of blood loss is not possible (e.g., ruptured aneurysm),~* Subjects for whom administration of intravenous vitamin K and vitamin K antagonists withdrawal alone can adequately correct the subject's coagulopathy before initiation of the urgent surgical procedure,~* Administration of intravenous vitamin K more than 3 hours or administration of oral vitamin K more than 6 hours prior to infusion of IMP,~* Subjects in whom lowering INR within normal range may present an unacceptable risk for a thromboembolic complication where the INR goal is to lower but not normalize the INR because of risk of a procedure-associated stroke,~* Subjects, who despite medical management that includes close monitoring and diuretics, may not, by investigator assessment, tolerate the total volume of IMP required by the protocol,~* Expected need for additional non-study blood products before infusion of IMP (Note: Administration of packed red blood cells is not an exclusion criterion),~* Expected need for platelet transfusions or desmopressin before Day 10,~* Acute trauma for which reversal of vitamin K antagonists alone would not be expected to control or resolve an acute bleeding complication and/or control the acute bleeding event,~* Unfractionated or low molecular weight heparin use within 24 hours before randomization or potential need before completion of the procedure,~* History of thromboembolic event, myocardial infarction, unstable angina pectoris, critical aortic stenosis, cerebral vascular accident, transient ischemic attack, severe peripheral vascular disease, disseminated intravascular coagulation within 3 months of enrollment,~* Reversal of VKA therapy alone may not resolve the coagulopathy (eg, receiving a potent anti-platelet agent, i.e., clopidogrel or prasugrel, or advanced liver disease),~* Known history of antiphospholipid antibody syndrome or lupus anticoagulant antibodies,~* Suspected or confirmed serious viral or bacterial infection, e.g., meningitis, or sepsis at time of enrollment,~* Administration of whole blood, plasma, plasma fractions or platelets within 2 weeks prior to inclusion into the study (Note: Administration of packed red blood cells is not an exclusion criterion),~* Pre-existing progressive fatal disease with a life expectancy of less than 2 months,~* Known inhibitors to coagulation factors II, VII, IX, or X; or hereditary protein C or protein S deficiency; or heparin-induced, type II thrombocytopenia,~* Treatment with any other investigational medicinal product within 30 days prior to inclusion into the study,~* Presence or history of hypersensitivity to components of the study medication,~* Pregnant or breast-feeding women,~* Prior inclusion in this study or any other CSL Behring sponsored Beriplex study,~* For subjects with intracranial hemorrhage with:~  * Glasgow Coma Score \<10 (see Appendix 8)~ * Modified Rankin Score \> 3 prior to ICH (see Appendix 9)~ * Intracerebral hemorrhage~ * Epidural hematomas~ * Infratentorial hemorrhage~ * Subarachnoid hemorrhage (SAH) subjects with a Hunt and Hess Scale \>2~ * Subdural hematomas that:~    * are judged to be an acute subdural hematoma (based on neurosurgeon review)~   * have a concurrent SAH or parenchymal contusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Beriplex® P/N (Type: EXPERIMENTAL): None
- Fresh frozen plasma (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).